These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 37519231)

  • 1. CFTR and PC2, partners in the primary cilia in autosomal dominant polycystic kidney disease.
    Yanda MK; Ciobanu C; Guggino WB; Cebotaru L
    Am J Physiol Cell Physiol; 2023 Sep; 325(3):C682-C693. PubMed ID: 37519231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zebrafish Model as a Screen to Prevent Cyst Inflation in Autosomal Dominant Polycystic Kidney Disease.
    Oliveira I; Jacinto R; Pestana S; Nolasco F; Calado J; Lopes SS; Roxo-Rosa M
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ameliorating liver disease in an autosomal recessive polycystic kidney disease mouse model.
    Yanda MK; Zeidan A; Cebotaru L
    Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G404-G414. PubMed ID: 36880660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector.
    Yanda MK; Liu Q; Cebotaru L
    J Biol Chem; 2018 Jul; 293(29):11513-11526. PubMed ID: 29875161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological reversal of renal cysts from secretion to absorption suggests a potential therapeutic strategy for managing autosomal dominant polycystic kidney disease.
    Yanda MK; Cha B; Cebotaru CV; Cebotaru L
    J Biol Chem; 2019 Nov; 294(45):17090-17104. PubMed ID: 31570523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro.
    Davidow CJ; Maser RL; Rome LA; Calvet JP; Grantham JJ
    Kidney Int; 1996 Jul; 50(1):208-18. PubMed ID: 8807590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VX-809 mitigates disease in a mouse model of autosomal dominant polycystic kidney disease bearing the R3277C human mutation.
    Yanda MK; Cebotaru L
    FASEB J; 2021 Nov; 35(11):e21987. PubMed ID: 34662459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease.
    Persu A; Devuyst O; Lannoy N; Materne R; Brosnahan G; Gabow PA; Pirson Y; Verellen-Dumoulin C
    J Am Soc Nephrol; 2000 Dec; 11(12):2285-2296. PubMed ID: 11095651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basolateral chloride transporters in autosomal dominant polycystic kidney disease.
    Lebeau C; Hanaoka K; Moore-Hoon ML; Guggino WB; Beauwens R; Devuyst O
    Pflugers Arch; 2002 Sep; 444(6):722-31. PubMed ID: 12355171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ouabain Regulates CFTR-Mediated Anion Secretion and Na,K-ATPase Transport in ADPKD Cells.
    Jansson K; Venugopal J; Sánchez G; Magenheimer BS; Reif GA; Wallace DP; Calvet JP; Blanco G
    J Membr Biol; 2015 Dec; 248(6):1145-57. PubMed ID: 26289599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cilia and polycystic kidney disease.
    Ma M
    Semin Cell Dev Biol; 2021 Feb; 110():139-148. PubMed ID: 32475690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The chloride channel CFTR is not required for cyst growth in an ADPKD mouse model.
    Talbi K; Cabrita I; Kraus A; Hofmann S; Skoczynski K; Kunzelmann K; Buchholz B; Schreiber R
    FASEB J; 2021 Oct; 35(10):e21897. PubMed ID: 34473378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Potential for CFTR Correctors in Autosomal Recessive Polycystic Kidney Disease.
    Yanda MK; Tomar V; Cebotaru L
    Cell Mol Gastroenterol Hepatol; 2021; 12(5):1517-1529. PubMed ID: 34329764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The heteromeric PC-1/PC-2 polycystin complex is activated by the PC-1 N-terminus.
    Ha K; Nobuhara M; Wang Q; Walker RV; Qian F; Schartner C; Cao E; Delling M
    Elife; 2020 Nov; 9():. PubMed ID: 33164752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic reduction of cilium length by targeting intraflagellar transport 88 protein impedes kidney and liver cyst formation in mouse models of autosomal polycystic kidney disease.
    Shao L; El-Jouni W; Kong F; Ramesh J; Kumar RS; Shen X; Ren J; Devendra S; Dorschel A; Wu M; Barrera I; Tabari A; Hu K; Haque N; Yambayev I; Li S; Kumar A; Behera TR; McDonough G; Furuichi M; Xifaras M; Lu T; Alhayaza RM; Miyabayashi K; Fan Q; Ajay AK; Zhou J
    Kidney Int; 2020 Nov; 98(5):1225-1241. PubMed ID: 32610050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycystin-2-dependent transcriptome reveals early response of autosomal dominant polycystic kidney disease.
    Jung HJ; Dixon EE; Coleman R; Watnick T; Reiter JF; Outeda P; Cebotaru V; Woodward OM; Welling PA
    Physiol Genomics; 2023 Nov; 55(11):565-577. PubMed ID: 37720991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease.
    Sundar SV; Zhou JX; Magenheimer BS; Reif GA; Wallace DP; Georg GI; Jakkaraj SR; Tash JS; Yu ASL; Li X; Calvet JP
    Am J Physiol Renal Physiol; 2022 Oct; 323(4):F492-F506. PubMed ID: 35979967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ciliary exclusion of Polycystin-2 promotes kidney cystogenesis in an autosomal dominant polycystic kidney disease model.
    Walker RV; Keynton JL; Grimes DT; Sreekumar V; Williams DJ; Esapa C; Wu D; Knight MM; Norris DP
    Nat Commun; 2019 Sep; 10(1):4072. PubMed ID: 31492868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis.
    Xu N; Glockner JF; Rossetti S; Babovich-Vuksanovic D; Harris PC; Torres VE
    J Nephrol; 2006; 19(4):529-34. PubMed ID: 17048214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibitors of intra-cystic secretion: novel therapies in ADPKD (Autosomal Dominant Polycystic Kidney Disease)].
    Miranda N; Miranda F; Rinaldi L; Stratigis S; Capasso G
    G Ital Nefrol; 2013; 30(1):. PubMed ID: 23832438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.